HRP20181657T1 - Postupak proizvodnje rekombinantog adamts13 u kulturi stanica - Google Patents

Postupak proizvodnje rekombinantog adamts13 u kulturi stanica

Info

Publication number
HRP20181657T1
HRP20181657T1 HRP20181657TT HRP20181657T HRP20181657T1 HR P20181657 T1 HRP20181657 T1 HR P20181657T1 HR P20181657T T HRP20181657T T HR P20181657TT HR P20181657 T HRP20181657 T HR P20181657T HR P20181657 T1 HRP20181657 T1 HR P20181657T1
Authority
HR
Croatia
Prior art keywords
cell culture
producing recombinant
recombinant adamts13
adamts13
producing
Prior art date
Application number
HRP20181657TT
Other languages
English (en)
Inventor
Leopold Grillberger
Manfred Reiter
Daniel Fleischanderl
Gregor Bramberger
Original Assignee
Baxalta GmbH
Baxalta Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44514323&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20181657(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxalta GmbH, Baxalta Incorporated filed Critical Baxalta GmbH
Publication of HRP20181657T1 publication Critical patent/HRP20181657T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HRP20181657TT 2010-07-08 2018-10-12 Postupak proizvodnje rekombinantog adamts13 u kulturi stanica HRP20181657T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36263510P 2010-07-08 2010-07-08
EP11738351.3A EP2591094B1 (en) 2010-07-08 2011-07-08 Method of producing recombinant adamts13 in cell culture
PCT/US2011/043459 WO2012006594A1 (en) 2010-07-08 2011-07-08 Method of producing recombinant adamts13 in cell culture

Publications (1)

Publication Number Publication Date
HRP20181657T1 true HRP20181657T1 (hr) 2019-03-08

Family

ID=44514323

Family Applications (3)

Application Number Title Priority Date Filing Date
HRP20192089TT HRP20192089T4 (hr) 2010-07-08 2011-07-08 Metoda proizvodnje rekombinanta visoke molekularne težine vwf u staničnoj kulturi
HRP20180136TT HRP20180136T1 (hr) 2010-07-08 2018-01-24 POSTUPAK PROIZVODNJE REKOMBINANTNOG VISOKOMOLEKULSKOG vWF U KULTURI STANICA
HRP20181657TT HRP20181657T1 (hr) 2010-07-08 2018-10-12 Postupak proizvodnje rekombinantog adamts13 u kulturi stanica

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HRP20192089TT HRP20192089T4 (hr) 2010-07-08 2011-07-08 Metoda proizvodnje rekombinanta visoke molekularne težine vwf u staničnoj kulturi
HRP20180136TT HRP20180136T1 (hr) 2010-07-08 2018-01-24 POSTUPAK PROIZVODNJE REKOMBINANTNOG VISOKOMOLEKULSKOG vWF U KULTURI STANICA

Country Status (25)

Country Link
US (8) US8852888B2 (hr)
EP (6) EP2590998B1 (hr)
JP (3) JP6138683B2 (hr)
KR (4) KR102027991B1 (hr)
CN (4) CN108060154A (hr)
AU (6) AU2011274470B2 (hr)
BR (2) BR112013000515B1 (hr)
CA (2) CA2804275A1 (hr)
CO (2) CO6680636A2 (hr)
DK (3) DK3064508T4 (hr)
EA (5) EA035066B1 (hr)
ES (4) ES2875772T3 (hr)
FI (1) FI3064508T4 (hr)
HR (3) HRP20192089T4 (hr)
HU (3) HUE11738351T2 (hr)
IL (5) IL286298B (hr)
MX (3) MX2013000166A (hr)
NZ (2) NZ605403A (hr)
PL (4) PL3064508T5 (hr)
PT (3) PT2590998T (hr)
SG (3) SG186935A1 (hr)
SI (3) SI3064508T2 (hr)
TR (1) TR201815211T4 (hr)
TW (4) TWI646972B (hr)
WO (2) WO2012006594A1 (hr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6111016B2 (ja) 2008-12-05 2017-04-05 バクスアルタ ゲーエムベーハー フォンビルブランド因子のａｄａｍｔｓ１３媒介インビボ切断を測定する方法およびその使用
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
BR112013000515B1 (pt) 2010-07-08 2021-11-03 Takeda Pharmaceutical Company Limited Método para produzir uma composição de fator von willebrand recombinante (rvwf)
KR101969515B1 (ko) 2011-06-10 2019-04-16 박스알타 인코퍼레이티드 재조합 vwf의 투여에 의한 응고 질환의 치료
US9030963B2 (en) * 2012-12-03 2015-05-12 Honeywell International Inc. Analyzing a network topology
UY35343A (es) * 2013-02-26 2014-09-30 Bayer Healthcare Llc Formulaciones y procedimientos para la producción de proteína recombinante aumentada
US20140271622A1 (en) * 2013-03-14 2014-09-18 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9677105B2 (en) 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
AU2013203062C1 (en) 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13
EP3131929B1 (en) 2014-04-16 2022-06-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the prevention or the treatment of bleeding episodes
EP3158055B1 (en) * 2014-06-13 2019-09-11 CSL Limited Improved production of recombinant von willebrand factor in a bioreactor
MA41685A (fr) 2014-10-17 2017-08-22 Biogen Ma Inc Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
CA2973343C (en) * 2015-02-05 2023-08-08 R.P. Scherer Technologies, Llc Activated formylglycine-generating enzymes and methods of producing and using the same
AR104050A1 (es) * 2015-03-26 2017-06-21 Chugai Pharmaceutical Co Ltd Proceso de producción con iones de cobre controlados
TW202330904A (zh) 2015-08-04 2023-08-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
EA201990373A1 (ru) 2016-08-04 2019-07-31 Баксалта Инкорпорэйтед Применение adamts13 для лечения, уменьшения интенсивности и/или предупреждения вазоокклюзивного криза при серповидноклеточной анемии, остром повреждении легкого и/или остром респираторном дистресс-синдроме
CN106957815B (zh) * 2017-03-16 2021-05-07 杨涛 一种用于人类多潜能干细胞的无血清培养基的配方
EP3648788B1 (en) 2017-07-07 2024-05-22 Takeda Pharmaceutical Company Limited Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf
CA3069256A1 (en) 2017-07-07 2019-01-10 Baxalta Incorporated Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant vwf
JP2021519280A (ja) 2018-03-21 2021-08-10 バクスアルタ インコーポレイテッド クロマトグラフィー法によるｖｗｆとｖｗｆプロペプチドの分離
CN113645993A (zh) 2019-02-01 2021-11-12 武田药品工业株式会社 使用重组VWF(rVWF)进行预防性治疗的方法
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
US10961500B1 (en) 2019-04-23 2021-03-30 Regeneron Pharmaceuticals, Inc. Cell culture medium for eukaryotic cells
JP2022547556A (ja) 2019-09-11 2022-11-14 武田薬品工業株式会社 フォン・ヴィレブランド因子と補体ｃ１ｑの複合体に関連する治療法
TW202134266A (zh) 2020-02-04 2021-09-16 日商武田藥品工業股份有限公司 藉由投予重組vwf治療患有嚴重馮威里氏病之患者之經血過多
US20230201319A1 (en) 2020-05-22 2023-06-29 Takeda Pharmaceutical Company Limited Adamts13 compositions and methods for treating and diagnosing complications of coronavirus disease

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
NL8500961A (nl) 1985-04-01 1986-11-03 Stichting Vrienden Van De Stic Cdna-codering voor de humane von willebrand-factor, plasmiden met een dergelijke cdna-codering respektievelijk fragmenten ervan, alsmede micro-organismen, welke dergelijke plasmiden bevatten.
AU591671B2 (en) 1985-04-11 1989-12-14 Children's Medical Center Corporation Von willebrand factor
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
DK0791055T3 (da) 1994-11-10 2012-04-16 Baxter Healthcare Sa Fremgangsmåde til fremstilling af biologiske produkter i proteinfri kultur
JP3649249B2 (ja) 1995-02-23 2005-05-18 クエスト・インターナショナル・サービシーズ・ビー・ブイ 組織および細胞培養用ペプチド
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
EP0953041A4 (en) 1996-08-30 2003-01-29 Life Technologies Inc SERUM-FREE CULTURAL MEDIUM FOR MAMMAL CELLS AND THEIR USE
US6458574B1 (en) 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
AU4751697A (en) 1996-10-10 1998-05-05 Douglas Danner Animal cell culture media comprising plant-derived nutrients
WO1998041611A1 (en) 1997-03-20 1998-09-24 Regents Of The University Of Minnesota Process for the continuous culture of cells
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
AT407255B (de) 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
US6528286B1 (en) * 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
US6406909B1 (en) 1998-07-10 2002-06-18 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
JP2001120262A (ja) 1999-10-26 2001-05-08 Welfide Corp 生理活性物質の産生増強方法
US6926894B2 (en) * 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
EP1453948A2 (en) * 2001-11-28 2004-09-08 Sandoz Gmbh Cell culture process
JP2005532033A (ja) 2002-01-17 2005-10-27 ロンザ・バイオロジクス・ピーエルシー タンパク質を産生する能力を有し且つ無グルタミン培地中で成長する能力を有するグルタミン栄養要求性ヒト細胞
US20050084828A1 (en) 2003-10-21 2005-04-21 The University Of North Carolina At Chapel Hill Apparatus and method for braille instruction
EP1593388A1 (en) 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
TWI384069B (zh) * 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US20060094104A1 (en) * 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
US8273553B2 (en) 2004-11-02 2012-09-25 Ares Trading S.A. Production of growth hormone in serum-free cell culture medium for mammalian cells
WO2006108455A1 (en) * 2004-11-02 2006-10-19 Ares Trading S.A. Serum-free cell culture medium for mammalian cells
US20070049557A1 (en) 2005-08-24 2007-03-01 Hashim Ahmed Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
PL2522717T3 (pl) 2006-01-04 2014-08-29 Baxalta Inc Pożywki do hodowli komórkowych wolne od oligopeptydów
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
CN101490239A (zh) * 2006-07-14 2009-07-22 帝斯曼知识产权资产管理有限公司 改进的细胞培养方法
MY161866A (en) * 2006-09-13 2017-05-15 Abbvie Inc Cell culture improvements
US7960869B2 (en) 2006-09-22 2011-06-14 Siemens Industry, Inc. Internal intelligence for remote operated relay
CN101678119B (zh) * 2006-12-27 2014-02-12 尼克塔治疗公司 具有可释放的键合的血管性血友病因子-和因子ⅷ-聚合物轭合物
DK2115126T3 (en) * 2007-03-02 2015-05-04 Wyeth Llc Use of copper and glutamate in cell culture for the preparation of polypeptides
DE102007046611A1 (de) * 2007-09-28 2009-04-02 Osram Opto Semiconductors Gmbh Lichtquelle mit Konversionselement und Lichtwellenleiter, Verfahren zur Herstellung der Lichtquelle und deren Verwendung
JP5727790B2 (ja) * 2007-12-27 2015-06-03 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 細胞培養プロセス
DK2240578T3 (da) 2007-12-31 2019-06-17 Baxalta GmbH I alt væsentligt dyreproteinfrit rekombinant furin og fremgangsmåder til fremstilling af samme
JP4458167B2 (ja) * 2008-01-11 2010-04-28 住友金属工業株式会社 熱間塑性加工用潤滑剤を用いる継目無管製造における外面潤滑方法
WO2009116044A2 (en) 2008-03-19 2009-09-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compounds for treating bacterial infections
AU2009236187B2 (en) * 2008-04-17 2012-08-02 Wyeth Llc Methods for enhanced production of bone morphogenetic proteins
US8486699B2 (en) 2008-05-23 2013-07-16 The United States Of America As Represented By The Secretary Of Agriculture Immortal unipotent porcine PICM-19H and PICM-19B stem cell lines
US8580554B2 (en) 2009-07-31 2013-11-12 Baxter International Inc. Method of producing a polypeptide or virus of interest in a continuous cell culture
CA2769361A1 (en) * 2009-07-31 2011-02-03 Baxter International Inc. Cell culture medium for adamts protein expression
BR112013000515B1 (pt) 2010-07-08 2021-11-03 Takeda Pharmaceutical Company Limited Método para produzir uma composição de fator von willebrand recombinante (rvwf)
TWI408228B (zh) 2010-10-29 2013-09-11 Univ Nat Chunghsing 用於生產一標的蛋白質的核酸建構物、重組型載體以及方法

Also Published As

Publication number Publication date
JP6138683B2 (ja) 2017-05-31
IL286298B (en) 2022-08-01
US10822394B2 (en) 2020-11-03
KR20130091328A (ko) 2013-08-16
SG186935A1 (en) 2013-02-28
CA2804275A1 (en) 2012-01-12
TWI609890B (zh) 2018-01-01
TW201206953A (en) 2012-02-16
US10100099B2 (en) 2018-10-16
CA2805557A1 (en) 2012-01-12
EP3909977A1 (en) 2021-11-17
AU2015207811A1 (en) 2015-08-20
IL255327A0 (en) 2017-12-31
US20170008948A1 (en) 2017-01-12
US8852888B2 (en) 2014-10-07
EP3392271B8 (en) 2021-06-16
ES2875772T3 (es) 2021-11-11
US20210115110A1 (en) 2021-04-22
TR201815211T4 (tr) 2018-11-21
DK3064508T3 (da) 2019-11-25
PT2590998T (pt) 2018-02-13
KR20180130587A (ko) 2018-12-07
KR101924120B1 (ko) 2018-11-30
PL3064508T3 (pl) 2020-02-28
HRP20192089T4 (hr) 2023-04-28
EA202090067A3 (ru) 2020-07-31
US20180044405A1 (en) 2018-02-15
MX2013000165A (es) 2013-06-05
CN103097409A (zh) 2013-05-08
US20150018525A1 (en) 2015-01-15
EP3626736A1 (en) 2020-03-25
AU2015207811B2 (en) 2017-10-19
KR101894604B1 (ko) 2018-09-03
ES2761692T5 (es) 2023-07-05
EP2590998B1 (en) 2017-11-15
AU2018200206B2 (en) 2020-05-28
EP2591094A1 (en) 2013-05-15
CN108060154A (zh) 2018-05-22
HRP20180136T1 (hr) 2018-04-06
EP2590998A1 (en) 2013-05-15
EA202090067A2 (ru) 2020-04-30
SI2590998T1 (en) 2018-06-29
PL2590998T3 (pl) 2018-05-30
SI2591094T1 (sl) 2018-12-31
KR20180099922A (ko) 2018-09-05
EP3064508B2 (en) 2023-03-15
EA201390080A1 (ru) 2013-06-28
NZ605404A (en) 2014-08-29
MX339632B (es) 2016-06-02
EP2591094B1 (en) 2018-09-05
PT2591094T (pt) 2018-11-20
EA202090220A2 (ru) 2020-05-31
AU2020203565B2 (en) 2021-09-30
PL3392271T3 (pl) 2021-11-15
SI3064508T2 (sl) 2023-05-31
KR20130091329A (ko) 2013-08-16
AU2011274470B2 (en) 2015-08-13
BR112013000515B1 (pt) 2021-11-03
JP6284919B2 (ja) 2018-02-28
JP5953502B2 (ja) 2016-07-20
PL2591094T3 (pl) 2019-02-28
HRP20192089T1 (hr) 2020-03-20
EP3392271A1 (en) 2018-10-24
PL3064508T5 (pl) 2024-04-08
EA029503B1 (ru) 2018-04-30
IL273304B (en) 2021-09-30
MX2013000166A (es) 2013-06-05
SG186936A1 (en) 2013-02-28
IL223929A (en) 2017-11-30
PT3064508T (pt) 2019-12-05
EA202090220A3 (ru) 2020-08-31
CN107286235A (zh) 2017-10-24
EP3064508A1 (en) 2016-09-07
DK2591094T3 (en) 2018-11-26
HUE046443T2 (hu) 2020-03-30
EA201792340A2 (ru) 2018-02-28
JP2013538046A (ja) 2013-10-10
TW201204744A (en) 2012-02-01
AU2011274467A1 (en) 2013-01-24
BR112013000512A2 (pt) 2016-05-17
EA201792340A3 (ru) 2018-07-31
TW201900207A (zh) 2019-01-01
EA201390082A1 (ru) 2013-06-28
TWI646972B (zh) 2019-01-11
ES2664392T3 (es) 2018-04-19
IL273304A (en) 2020-04-30
AU2011274467B2 (en) 2015-01-15
ES2694518T3 (es) 2018-12-21
CN103097522A (zh) 2013-05-08
DK2590998T3 (en) 2018-02-12
EP3392271B1 (en) 2021-05-05
IL223930A (en) 2017-01-31
US20150056657A1 (en) 2015-02-26
DK3064508T4 (da) 2023-04-11
TWI617575B (zh) 2018-03-11
CO6690745A2 (es) 2013-06-17
US11780904B2 (en) 2023-10-10
US20190085052A1 (en) 2019-03-21
JP2017217004A (ja) 2017-12-14
BR112013000515A2 (pt) 2016-05-17
WO2012006594A1 (en) 2012-01-12
EA035066B1 (ru) 2020-04-23
SI3064508T1 (sl) 2019-12-31
US9409971B2 (en) 2016-08-09
AU2022200035A1 (en) 2022-01-20
SG10201809632XA (en) 2018-12-28
IL255327B (en) 2020-04-30
AU2020203565A1 (en) 2020-06-18
US9834591B2 (en) 2017-12-05
US9458222B2 (en) 2016-10-04
AU2018200206A1 (en) 2018-04-05
JP2016025873A (ja) 2016-02-12
KR102007773B1 (ko) 2019-08-06
WO2012006591A1 (en) 2012-01-12
ES2761692T3 (es) 2020-05-20
MX353409B (es) 2018-01-11
TWI670073B (zh) 2019-09-01
JP2013533748A (ja) 2013-08-29
NZ605403A (en) 2014-10-31
IL286298A (en) 2021-10-31
US20120034674A1 (en) 2012-02-09
EP3064508B1 (en) 2019-08-28
CO6680636A2 (es) 2013-05-31
AU2011274470A1 (en) 2013-01-24
HUE11738351T2 (hu) 2019-03-28
EA035147B1 (ru) 2020-05-06
KR102027991B1 (ko) 2019-10-02
TW201637665A (zh) 2016-11-01
HUE038193T2 (hu) 2018-09-28
US20120035110A1 (en) 2012-02-09
FI3064508T4 (fi) 2023-04-25

Similar Documents

Publication Publication Date Title
HRP20181657T1 (hr) Postupak proizvodnje rekombinantog adamts13 u kulturi stanica
HRP20182165T1 (hr) Postupak proizvodnje polipeptida ili virusa od interesa u kontinuiranoj staničnoj kulturi
HRP20190484T1 (hr) Pripravci stanične kulture i postupci proizvodnje polipeptida
IL242092A0 (en) A method for eukaryotic cell culture
EP2530729A4 (en) SOLAR CELL AND METHOD OF MANUFACTURING THE SAME
GB201111302D0 (en) Solar cell and method for producing same
EP2651207A4 (en) METHOD FOR IMPROVING THE COMPETENCE OF PLANT CELLS
IL222454A0 (en) Improved cell cultivation process
EP2612902A4 (en) TEMPERATURE-REACTIVE SUBSTRATE FOR CELL CULTURE AND PROCESS FOR PRODUCTION OF SAID SUBSTRATE
EP2628789A4 (en) CULTURE CONTAINER FOR ADHERENT CELLS, AND METHOD FOR MANUFACTURING CULTURE CONTAINER FOR ADHESIVE CELLS
EP2700707A4 (en) CELL CULTURE METHOD AND CELL CULTURE KIT
GB201113641D0 (en) Cell culture support and cell culture method
EP2628239A4 (en) PROCESS AND SUBSTRATES FOR THE MANUFACTURE OF PHOTOVOLTAIC CELLS
EP2702615A4 (en) SOLAR CELL AND MANUFACTURING METHOD THEREFOR
EP2686423A4 (en) METHOD FOR PRODUCING VIRUSES IN CELLS
EP2383331A4 (en) METHOD FOR PRODUCING A CELL CULTURAL FRAME
GB201005736D0 (en) Electrolysis cell and method of operation
IL223178A0 (en) Photovoltaic cell and method of its manufacture
GB201020075D0 (en) Mammalian cell transformation method
GB201007855D0 (en) Bioreactor for the culture of cells
GB201120446D0 (en) Mammalian cell transformation method
GB201007863D0 (en) Bioreactor for cell culture